Trending...
- Talentica Announces Winners of Multi-Agent Hackathon 2026
- Kaltra Introduces New Downward-Spraying Distribution Technology to Boost Microchannel Evaporator Performance
- Amicly Launches as a Safety-First Social App Designed to Help People Build Real, Meaningful Friendships
BOSTON, May 20, 2024 ~ Journalist: HotSpot Therapeutics, Inc. has announced that they will be presenting additional preclinical data from their MALT1 program at the 4th American Association for Cancer Research (AACR) International Meeting. The meeting, titled "Advances in Malignant Lymphoma," will take place from June 19-22, 2024 in Philadelphia, PA.
The company, known for pioneering the discovery and development of oral, small molecule allosteric therapies targeting regulatory sites on proteins referred to as "natural hotspots," will be sharing their findings on the highly differentiated mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) program.
More on The PennZone
The presentation, titled "Targeting the CBM Signalosome with a MALT1 Scaffolding Inhibitor for Treatment of Non-Hodgkin Lymphomas," will take place on Thursday, June 20, 2024 from 5:30-7:30 PM ET at the Sheraton Philadelphia Downtown. The publication number for this presentation is PO-036.
HotSpot Therapeutics' innovative approach to targeting regulatory sites on proteins has shown promising results in their MALT1 program and could potentially lead to new treatments for non-Hodgkin lymphomas. The company's participation in the AACR International Meeting highlights their commitment to advancing cancer research and finding new ways to treat this disease.
The company, known for pioneering the discovery and development of oral, small molecule allosteric therapies targeting regulatory sites on proteins referred to as "natural hotspots," will be sharing their findings on the highly differentiated mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) program.
More on The PennZone
- Seven-Year-Old Toronto Dancer Julianna Selivanov Wins Nine Medals at Quebec Championship and Reaches Finals at UK Dance Festival
- Pa. Department of Environmental Protection Approves Keystone Consulting Engineers as a Qualified Professional in its SPEED Program
- Progressive Dental & The Closing Institute Partner with Zest Dental Solutions to Elevate Full-Arch Growth and Patient Outcomes
- Spring Surge in 55+ Communities: What Buyers and Sellers Need to Know in 2026
- Jason Caras Launches The Caras Institute Following Successful Exit from IT Authorities
The presentation, titled "Targeting the CBM Signalosome with a MALT1 Scaffolding Inhibitor for Treatment of Non-Hodgkin Lymphomas," will take place on Thursday, June 20, 2024 from 5:30-7:30 PM ET at the Sheraton Philadelphia Downtown. The publication number for this presentation is PO-036.
HotSpot Therapeutics' innovative approach to targeting regulatory sites on proteins has shown promising results in their MALT1 program and could potentially lead to new treatments for non-Hodgkin lymphomas. The company's participation in the AACR International Meeting highlights their commitment to advancing cancer research and finding new ways to treat this disease.
Filed Under: Business
0 Comments
Latest on The PennZone
- Summit Appoints Javier Cabeza as Data, AI, and Analytics Practice Lead
- TrueNorth Wellness Services is Excited to Participate in Give Local York
- March Is Skiing's Smartest Buying Window
- Hope Survives Launches The Hope Collective, A Curated Publication Centering Lived Experience After Brain Injury
- Cancun Airport Transportation Expands Fleet Ahead of Record Passenger Growth at Cancun International Airport
- Tobu Group's "T-home Series" of Accommodations in Tokyo Just Opened "T-home KEI."
- Custom Wooden Token Manufacturer Celebrates 10 Years of Helping Brands Stay Top of Mind
- NaturismRE Launches the NRE Health Institute to Advance Evidence-Informed Public Health Research
- P-Wave Classics to publish Robert Bage's Hermsprong in three volumes, beginning 12 May
- Progressive Dental & The Closing Institute Partner with Zest Dental Solutions to Elevate Full-Arch Growth and Patient Outcomes
- Kilmaine Saints to Record Live Album at XL Live
- CCHR: While Damaging Antipsychotics Win Approval, Proven Non-Drug Alternatives Remain Ignored
- Arcuri Group Announces Long‑Term Partnership with WakeMed Health & Hospitals to Deliver Situational Awareness and De‑escalation Training
- KDG Announces Acquisition of Square Foot Consultants, Expanding Business and Technology Expertise
- Colonial Nissan Service Named Top 5 Auto Repair in Feasterville-Trevose for 2025
- At 25, She Became One of the Youngest AAPI Female Founders to Win One of the World's Most Prestigious Design Awards for a Lamp That Makes You Smile
- Juego Studios Extends Full-Cycle Game Development & Outsourcing Capabilities to the UAE Market
- VENUS Goes Live on CATEX Exchange As UK Financial Ltd Activates The Premier Division Of The Maya Meme's League
- Atlanta Tech Founder Seeks Clarity on Intellectual Property and Innovation Policy
- Purple Heart Recipient Honored by Hall of Fame Son In Viral Tribute Sparking National Conversation on Service Fatherhood, Healing and Legacy